FDA Approves Lutetium Lu 177 Vipivotide Tetraxetan for PSMA+ mHSPC

The FDA has approved lutetium Lu 177 vipivotide tetraxetan plus an androgen receptor pathway inhibitor for treatment of PSMA-positive metastatic hormone-sensitive prostate cancer, based on phase 3 trial data demonstrating reduced progression risk and potential overall survival benefits.

This Wire brief sits within Fusion42's coverage of Biotech. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.